Elelyso

Chemical Nametaliglucerase alfa
Dosage FormInjection (intravenous; 200 units/vial)
Drug ClassEnzymes
SystemBlood
CompanyPfizer
Approval Year2012

Indication

  • For the treatment of type 1 Gaucher disease in patients 4 years and older with a confirmed diagnosis
Last updated on 4/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Elelyso (taliglucerase alfa) Prescribing Information.2012Pfizer Inc., New York, NY
Document TitleYearSource
Enzyme replacement and substrate reduction therapy for Gaucher disease. 2015The Cochrane Database of Systematic Reviews